Incidence of Ototoxicity caused by platinum-based chemotherapy in Thai non-head and Neck irradiated cancerous patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20130922001

Enrollment

Registered

2013-09-22

Start date

2013-09-22

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ototoxicity Sensorineural hearing loss High frequency hearing loss Toxic labyrinthitis

Interventions

Cisplatin or Carboplatin

Experimental Drug

Plantinum based chemotherapeutic agents

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. new case of cancer patients who never receive chemotherapy, Is planned to receive platinum-based chemotherapy and is 20 years old or older. 2. having life expectancy more than 6 months or good performance (Karnofsky score > 60 or ECOG 0-1), 3. having normal liver function test, 4. Having normal GFR or CrCl > 50 ml/min (in case of carboplatin CrCl > 30 ml/min), 5. volunteer to participate

Exclusion criteria

Exclusion criteria: 1. previous head and neck irradiation 2. having external ear disease or middle ear abnormality 3. being diagnosed as Meniere 's disease or Meniere 's syndrome or retrocochlear lesion 4.cannot cooperate with the conventional and ultrahigh frequency audiometry

Design outcomes

Primary

Measure	Time frame
Hearing loss 6 cycles Utrahigh frequency audiometry	—

Secondary

Measure	Time frame
absence emission 6 cycles distortion producted otoacoustic emission	—

Contacts

Public ContactKwanchanok Yimtae

Khon Kaen University

kwayim@kku.ac.th+66868541515

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026

Incidence of Ototoxicity caused by platinum&#45;based chemotherapy in Thai non&#45;head and Neck irradiated cancerous patients